On November 19, 2025, Daping Hospital and the Research Institute of Surgery at the Third Military Medical University announced a pivotal clinical trial exploring a novel surgical approach for gastric cancer patients. The study, titled “Single-port Robotic Radical Gastrectomy for Gastric Cancer,” is set to investigate the feasibility, performance, and outcomes of utilizing single-port robotic technology in radical gastrectomy procedures. The trial is currently marked as not yet recruiting.
In this article:
- What is Single-port Robotic Gastrectomy?
- Clinical Trial Scope
- Patient Eligibility
- Frequently Asked Questions
- Conclusion
- Disclaimer
- Complete Announcement
What is Single-port Robotic Gastrectomy?
Single-port robotic radical gastrectomy is an advanced surgical technique designed to improve precision, reduce invasiveness, and accelerate recovery. Unlike traditional laparoscopic methods or multi-port systems, this procedure utilizes a single access point for the robotic system to perform complex oncological resections with enhanced maneuverability and visualization.
The procedure is being considered for widespread adoption due to its potential to provide better clinical outcomes, mitigate post-surgical complications, and optimize surgical ergonomics. However, further evidence from clinical trials is necessary to validate its safety and efficacy.
Clinical Trial Scope
The trial will assess how well single-port robotic systems perform radical gastrectomy procedures for patients with gastric cancer. As stated by the sponsor, the goals are to analyze technical feasibility, oncological safety, and postoperative recovery outcomes. Researchers aim to establish a reliable dataset that regulatory committees and healthcare institutions can use for future decision-making.
This trial, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, is registered under the identifier NCT07237126 on ClinicalTrials.gov. Recruitment efforts have not started.
Patient Eligibility
The primary condition addressed in this study is gastric cancer requiring surgical intervention. All patients undergoing radical gastrectomy for gastric cancer may potentially qualify for the study depending on predefined inclusion and exclusion criteria, which have not been publicly outlined yet.
Interested participants and medical teams should monitor ClinicalTrials.gov for detailed eligibility criteria once recruitment begins.
Frequently Asked Questions
- Q: What distinguishes single-port robotic surgery?
A: It uses one port instead of multiple access points, delivering superior precision with reduced tissue trauma. - Q: Who is conducting the trial?
A: The trial is backed by Daping Hospital and the Third Military Medical University. - Q: Is the trial currently recruiting?
A: No, recruitment has not started yet, as indicated in the registry. - Q: Where can I learn more?
A: Visit the official registry entry at ClinicalTrials.gov under NCT07237126.
Conclusion
The upcoming clinical trial for single-port robotic radical gastrectomy represents a significant milestone in surgical oncology innovation. Clinicians, regulators, and healthcare strategists are encouraged to follow this development closely as it unfolds.
Further updates about patient recruitment and trial milestones will likely emerge soon, solidifying the foundation for breakthroughs in gastric cancer treatment protocols.
Disclaimer
The content provided is informational and intended for professional discussions regarding clinical and medical device regulatory developments. It does not constitute legal advice or professional guidance.
Complete Announcement
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07237126?term=medical+device